DCM
RIGL icon

Delpha Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Delpha Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-302
Closed -$12K – 981
2017
Q4 		$12K Buy
+302
New +$11.5K 0.01% 1005

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Delpha Capital Management's RIGL Position: Q1 2018 in Review

Delpha Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2018, closing a stake of 302 shares — an estimated $12K sold.

Delpha Capital Management first reported a position in RIGL in Q4 2017 and held it in 1 quarter. The position peaked at $12K in Q4 2017. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2018.

  • Delpha Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 302 Rigel Pharmaceuticals shares in Q1 2018, an estimated $12K.
  • Delpha Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Rigel Pharmaceuticals position peaked at $12K in Q4 2017.
  • 117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.